Biotron (BIT) Price & Analysis

Q: What is Biotron Limited’s market cap?

Biotron Limited’s market cap is AU$9.46M.

Q: When is Biotron Limited’s upcoming earnings report date?

Biotron Limited’s upcoming earnings report date is Mar 04, 2026 which is in 11 days.

Q: How were Biotron Limited’s earnings last quarter?

Biotron Limited released its earnings results on Aug 27, 2025. The company reported -AU$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.001.

Q: Is Biotron Limited overvalued?

According to Wall Street analysts Biotron Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Biotron Limited pay dividends?

Biotron Limited does not currently pay dividends.

Q: What is Biotron Limited’s EPS estimate?

Biotron Limited’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Biotron Limited have?

Biotron Limited has 2,701,866,000 shares outstanding.

Q: What happened to Biotron Limited’s price movement after its last earnings report?

Biotron Limited reported an EPS of -AU$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.143%.

Q: Which hedge fund is a major shareholder of Biotron Limited?

Currently, no hedge funds are holding shares in AU:BIT

Compare

28 Followers

BIT Stock Chart & Stats

AU$0.01

<AU$0.01(6.25%)

At close: Jan 09 4:00 PM EST

AU$0.01

<AU$0.01(6.25%)

Day’s Range― - ―

52-Week Range<AU$0.01 - AU$0.11

Previous CloseN/A

Volume463.29K

Average Volume (3M)1.60M

Market Cap

AU$9.46M

Enterprise ValueAU$4.88M

Total Cash (Recent Filing)AU$931.68K

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta1.66

Next Earnings

Mar 04, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding2,701,866,000

10 Day Avg. Volume3,265,462

30 Day Avg. Volume1,601,469

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)3.63

Price to Sales (P/S)1.10

P/FCF Ratio-3.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Debt LevelsA low-debt balance sheet reduces financial risk, providing Biotron with greater flexibility to invest in R&D and strategic initiatives without the burden of high interest expenses.

Strategic AcquisitionThe acquisition of Sedarex Limited enhances Biotron's product pipeline with a late-stage clinical asset, potentially accelerating growth and diversification in the antiviral and neuroscience fields.

Management StrengthThe appointment of Dr. Paul Kasian, with extensive experience in life sciences, strengthens Biotron's governance and strategic direction, potentially improving its business development capabilities.

Bears Say

Negative Cash FlowPersistent negative cash flow indicates ongoing reliance on external funding, which could limit Biotron's ability to sustain operations and invest in growth without raising additional capital.

Volatile RevenueVolatile revenue streams can hinder Biotron's ability to plan long-term investments and may affect investor confidence, impacting the company's ability to secure funding and partnerships.

Continued LossesOngoing losses reflect challenges in achieving profitability, which may strain Biotron's financial resources and limit its capacity to invest in R&D and market expansion.

Biotron News

Biotron Director Robert Thomas Retires After 14 Years on Board

Biotron ( ($AU:BIT) ) has issued an announcement. Biotron Limited has announced the retirement of non-executive director Robert...

16d ago

Biotron Completes Fully Subscribed Offer and Bolsters Board

Biotron ( ($AU:BIT) ) just unveiled an announcement. Biotron Limited has confirmed that its recent capital raising under...

23d ago

Biotron Seeks ASX Quotation for Major Share and Option Issue

The latest announcement is out from Biotron ( ($AU:BIT) ). Biotron Limited has applied to the ASX for...

23d ago

Biotron Completes Fully Subscribed Rights Issue to Fund Diversified Portfolio

Biotron ( ($AU:BIT) ) just unveiled an announcement. Biotron Limited has successfully completed its non-renounceable rights issue, with...

23d ago

Biotron Expands with Sedarex Acquisition and Reports Strong Preclinical HBV Drug Data

The latest update is out from Biotron ( ($AU:BIT) ). Biotron Limited’s December 2025 quarter was marked by...

24d ago

Biotron Directors Lift Holdings Through Rights Issue Participation

Biotron ( ($AU:BIT) ) has shared an update. Biotron Limited has notified the ASX of changes in directors’...

2M ago

Biotron Seeks ASX Quotation for 181.7 Million New Options

An update from Biotron ( ($AU:BIT) ) is now available. Biotron Limited has lodged an application with the...

2M ago

Biotron Withdraws Appendix 3G, To Refile Equity Notice as Appendix 2A

The latest update is out from Biotron ( ($AU:BIT) ). Biotron Limited has withdrawn a previously lodged Appendix...

2M ago

Biotron Appoints Veteran Life Sciences Executive Paul Kasian as Non-Executive Director

Biotron ( ($AU:BIT) ) has shared an update. Biotron Limited has appointed experienced life sciences executive and board...

2M ago

Biotron Shares Reinstated to Quotation on ASX

The latest update is out from Biotron ( ($AU:BIT) ). Biotron Limited has had its ordinary shares (trading...

2M ago

BIT FAQ

What was Biotron Limited’s price range in the past 12 months?

Biotron Limited lowest share price was <AU$0.01 and its highest was AU$0.11 in the past 12 months.

What is Biotron Limited’s market cap?

Biotron Limited’s market cap is AU$9.46M.

When is Biotron Limited’s upcoming earnings report date?

Biotron Limited’s upcoming earnings report date is Mar 04, 2026 which is in 11 days.

How were Biotron Limited’s earnings last quarter?

Biotron Limited released its earnings results on Aug 27, 2025. The company reported -AU$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.001.

Is Biotron Limited overvalued?

According to Wall Street analysts Biotron Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Biotron Limited pay dividends?

Biotron Limited does not currently pay dividends.

What is Biotron Limited’s EPS estimate?

Biotron Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Biotron Limited have?

Biotron Limited has 2,701,866,000 shares outstanding.

What happened to Biotron Limited’s price movement after its last earnings report?

Biotron Limited reported an EPS of -AU$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.143%.

Which hedge fund is a major shareholder of Biotron Limited?

Currently, no hedge funds are holding shares in AU:BIT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Biotron Stock Smart Score

Underperform

Blogger Sentiment

Bullish

AU:BIT Sentiment 70%
Sector Average ―

Insider Transactions

Bought Shares

Worth AU$83.4K over
the Last 3 Months

Fundamentals

Return on Equity

-184.73%

Trailing 12-Months

Asset Growth

94.95%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Biotron Limited

Biotron Limited (BIT) is a biotechnology company focused on the development of novel therapeutics for the treatment of serious viral infections. The company operates primarily in the pharmaceutical and biotechnology sectors, with a core emphasis on research and development of antiviral drugs targeting viruses such as HIV-1 and Hepatitis C.